Form 4: Zoetis Director Hattersley Receives RSU Grants

Zoetis Inc. Director Gavin Hattersley reported the grant of restricted stock units, vesting in 2025 and 2026.

Summary

• Gavin Hattersley, a Director of Zoetis Inc. (ZTS), reported the acquisition of Restricted Stock Units (RSUs).
• A grant of 1,936 RSUs was made, which will vest and settle into shares of Zoetis Inc. common stock on February 18, 2026.
• Another grant of 1,619.3325 RSUs was made, which will vest and settle into shares of Zoetis Inc. common stock on February 19, 2025.
• These RSUs are granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan.
• Each RSU represents a contingent right to receive one share of Zoetis Inc. common stock, subject to the reporting person's continued service through the respective vesting dates.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting standard executive compensation practices that align director interests with long-term company performance, without indicating any immediate operational or financial changes.

Positives

• The grant of Restricted Stock Units aligns the director's long-term interests with shareholder value.
• Equity compensation is a standard practice to incentivize and retain key personnel within the company.

Risks

• The vesting of the Restricted Stock Units is contingent upon Gavin Hattersley's continued service through the specified vesting dates, meaning the shares could be forfeited if service terminates earlier.

Future Outlook

The future outlook indicates that Gavin Hattersley is expected to continue his service as a director through the vesting dates of February 19, 2025, and February 18, 2026, to receive the common stock from the RSU grants.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units to a director is a standard practice in the animal health and pharmaceutical industry, aligning executive incentives with long-term company performance and shareholder interests. This type of equity compensation is common across publicly traded companies to retain and motivate key leadership.

Comparison to Industry Standards

• This RSU grant is consistent with typical executive compensation structures observed in large-cap animal health and pharmaceutical companies such as Merck & Co. (MRK), Elanco Animal Health (ELAN), and IDEXX Laboratories (IDXX).
• Equity awards form a significant component of director and executive remuneration in these industries.
• The vesting schedule, contingent on continued service, is a standard mechanism to promote long-term commitment and retention.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns their interests with long-term shareholder value, as the value of the compensation is tied to the company's stock performance.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• Continued service of Gavin Hattersley through February 19, 2025, for the vesting of 1,619.3325 RSUs.
• Continued service of Gavin Hattersley through February 18, 2026, for the vesting of 1,936 RSUs.
• Settlement of vested RSUs into shares of Zoetis Inc. common stock on the respective vesting dates.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of Restricted Stock Units to a director, which is a standard component of executive compensation. It does not contain information that would fundamentally alter the investment thesis for Zoetis Inc., nor does it suggest any immediate catalysts for significant price movement. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific disclosure.

Keywords

Zoetis, ZTS, Restricted Stock Units, RSU, Equity Compensation, Director Compensation, SEC Form 4, Insider Transaction